Information Dissemination System
Phone: +43 1/319 14 56-336
Fax: +43 1/319 14 56-316
Mr. Dr. Klaus Gerdes, CMO
Mrs. Dr. Christina Abrahamsberg, CSO
The strategic focus is on fast-growing pharmaceutical markets as well as the consolidation of existing sales markets and areas with high demand for high-quality diagnostic imaging (contrast media) and therapeutics. With a comprehensive network of subsidiaries and distribution partnerships, SANOCHEMIA is well positioned internationally and is successfully expanding into emerging global pharmaceutical markets. SANOCHEMIA has an established portfolio of human and veterinary pharmaceuticals and continues to develop its research and development. The focus is on products to expand Sanochemias portfolio, such as the development of efficient cancer diagnostics such as Vidon® for the photodynamic diagnosis of bladder cancer or other contrast products, especially in the field of magnetic resonance examinations. In the veterinary field, especially the segment of the so-called hobby animals opens up additional growth opportunities.
As a fully integrated pharmaceutical company, SANOCHEMIA unites all essential steps of the value chain under one roof: from the production of active ingredients to the production, marketing and distribution of pharmaceuticals and diagnostics. The company already has an increasing share of its sales in emerging markets, which are very dynamic and have above-average growth rates. With the step to North America, new growth prospects can be opened in all business areas.
|02/14/2019||Publication of the annual results 2017/18, press conference|
|02/21/2019||Publication of the interim report for the 1st quarter 2018/19|
|03/18/2019||Record date "Annual General Meeting"|
|03/28/2019||Annual General Meeting, Eisenstadt|
|05/23/2019||Publication of the half-yearly report 2018/19|
|09/05/2019||Publication of the interim report for the 3rd quarter 2018/19|
Source: provided by the company
Record date "Dividends": Date on which settled positions are struck in the books of the Issuer`s CSD at close of business to determine the entitlement to dividends. Origination of entitlement is still linked to the Ex-dividend date.
Record date "Annual General Meeting": Date for participation to Annual General Meeting.